Compare Abeona Therapeutics Inc (ABEO) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Annaly Capital Management, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Annaly Capital Management, Inc. trades at $22.61 (market cap $16.63B). The key difference: Annaly Capital Management, Inc. is far larger — about 44.5× Abeona Therapeutics Inc's market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NLY | |
|---|---|---|
Market Cap | $373.32M | $16.63B |
Sector | Health | Financials |
52-Week High | $7.23 | $24.40 |
52-Week Low | $4.17 | $19.47 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Annaly Capital Management (NLY) trades at $22.69, up 0.58% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 7.42, ROE of 15.61%, and consistent earnings beats in recent quarters. Recent dividend increases to $0.75 per share and positive analyst coverage highlight income appeal. The company maintains solid liquidity despite significant investing outflows.
NLY presents a compelling income opportunity with a 13.2% dividend yield and analyst consensus target of $24.40. However, risks include interest rate sensitivity, high leverage (debt-to-asset ratio of 23.55), and volatile cash flow patterns. The stock offers 7.5% upside potential but requires monitoring of Federal Reserve policy impacts on mortgage REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
